Biotest on track to achieve climate neutrality
Last year the company reduced its electricity requirements by 40%
Aware of its energy-intensive production and the resulting impact on the environment, plasma proteins and biological drugs provider Biotest has and is continuing to make significant changes at its Dreieich (Germany) site to combat climate change through CO2-neutral production.
For years, the company has been running a certified energy management system to systematically collect data, present it and tap potential for optimisation in an effot to reduce energy consumption and greenhouse gas emissions.
Similarly, Biotest has been operating highly efficient combined heat and power plants, meaning that in addition to generating electricity for its own needs, the waste heat is also used to air-condition buildings throughout the year.
Last year, Biotest replaced an air conditioning system, which reduced their electricity requirements by 40%. The annual electricity savings from this one project equate to the electricity consumption of approximately 50 households.
Additional targeted measures the company has undertaken include replacing light bulbs, installing electric charging stations for cars, optimising the running time of technical equipment and using natural refrigerants for its cold storage facilities.
The company is currently planning to install photovoltaic systems, which convert light into electric power, on its premises.
To make the remaining energy consumption climate-neutral despite all the measures listed, Biotest obtains its electricity (approximately 30 million kWh) from renewable sources.
Any remaining greenhouse gas emissions generated at the site are offset by voluntary investments in non-profit climate protection projects, such as promoting access to clean energy for communities in rural Vietnam by building biogas plants.
The company says it is also supporting the local campaign to convert monostructural forest areas into climate-stable mixed forests in the Dreieich municipal forest.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.